Paloma Montero‐Escribano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Paloma Montero‐Escribano has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Jordi A. Matias-Guiu
Hospital Clinico San Carlos
8 shared publications - Ulises Gómez-Pinedo
Laboratorio de Neurobiología y Terapias Avanzadas, Instituto de Neurociencias, Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico San Carlos, 28040 Madrid, Spain
7 shared publications - Laura Torre‐Fuentes
VISAVET Health Surveillance Centre, Complutense University of Madrid
5 shared publications - Vanesa Pytel
Department of Neurology, Hospital Clınico San Carlos, San Carlos Health Research Institute (IdISSC), Universidad Complutense de Madrid, Madrid, Spain
5 shared publications - Belen Selma-Calvo
Laboratorio de Neurobiología y Terapias Avanzadas, Instituto de Neurociencias, Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico San Carlos, 28040 Madrid, Spain
4 shared publications - Doddy Denise Ojeda-Hernández
Laboratorio de Neurobiología y Terapias Avanzadas, Instituto de Neurociencias, Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico San Carlos, 28040 Madrid, Spain
4 shared publications
Latest Publications
- Open Access
- 6 March 2025
- Published by Elsevier in Neurología
- Vol. 40 (2) , 150-160
Exonic variants of the P2RX7 gene in familial multiple sclerosis
- 6 March 2025
- Published by Elsevier in Neurología
- Vol. 40 (2) , 150-160
Open AccessExonic variants of the P2RX7 gene in familial multiple sclerosis
- Open Access
- 15 January 2025
- Published by Elsevier in Neurología
- Vol. 40 (1) , 10-21
Variant rs4149584 (R92Q) of the TNFRSF1A gene in patients with familial multiple sclerosis
- 15 January 2025
- Published by Elsevier in Neurología
- Vol. 40 (1) , 10-21
Open AccessVariant rs4149584 (R92Q) of the TNFRSF1A gene in patients with familial multiple sclerosis
- Open Access
- 5 December 2022
- Published by Elsevier in Neurología (English Edition)
- Vol. 40 (2) , 150-160
Exonic variants of the P2RX7 gene in familial multiple sclerosis
- 5 December 2022
- Published by Elsevier in Neurología (English Edition)
- Vol. 40 (2) , 150-160
Open AccessExonic variants of the P2RX7 gene in familial multiple sclerosis
- Open Access
- 10 August 2022
- Published by Elsevier in Neurología (English Edition)
- Vol. 40 (1) , 10-21
Variant rs4149584 (R92Q) of the TNFRSF1A gene in patients with familial multiple sclerosis
- 10 August 2022
- Published by Elsevier in Neurología (English Edition)
- Vol. 40 (1) , 10-21
Open AccessVariant rs4149584 (R92Q) of the TNFRSF1A gene in patients with familial multiple sclerosis
- Open Access
- 20 September 2020
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 26 (11) , 1178-1184
Variants of genes encoding TNF receptors and ligands and proteins regulating TNF activation in familial multiple sclerosis
Introduction: Numerous genetic variants have been associated with susceptibility to multiple sclerosis (MS). Variants located in genes involved in specific pathways, such as those affecting TNF‐α, can contribute to the risk of MS. The purpose of this study was to determine whether variants of these genes are associated with greater risk of MS.Methods: We used whole‐exome sequencing to study genes coding for TNF‐α receptors and ligands, and proteins promoting TNF‐α expression in 116 individuals from 19 families including at least two MS patients. We compared patients with MS, patients with other autoimmune diseases, and healthy individuals.Results: Greater polymorphism was observed in several genes in families with familial MS compared to the general population; this may reflect greater susceptibility to autoimmune diseases. Pedigree analysis also revealed that LT‐α variants rs1041981 and rs2229094 and LT‐β variant rs4647197 were associated with MS and that LT‐β variant rs4647183 was associated with other autoimmune diseases. The association between autoimmune disease and TNFAIP2 variant rs1132339 is particularly noteworthy, as is the fact that TNFAIP6 variant rs1046668 appears to follow a recessive inheritance pattern.Conclusions: Our findings support the idea that the risk of familial MS is associated with variants of signaling pathways, including those involving TNF‐α.
- 20 September 2020
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 26 (11) , 1178-1184
Open AccessVariants of genes encoding TNF receptors and ligands and proteins regulating TNF activation in familial multiple sclerosis
Introduction: Numerous genetic variants have been associated with susceptibility to multiple sclerosis (MS). Variants located in genes involved in specific pathways, such as those affecting TNF‐α, can contribute to the risk of MS. The purpose of this study was to determine whether variants of these genes are associated with greater risk of MS.Methods: We used whole‐exome sequencing to study genes coding for TNF‐α receptors and ligands, and proteins promoting TNF‐α expression in 116 individuals from 19 families including at least two MS patients. We compared patients with MS, patients with other autoimmune diseases, and healthy individuals.Results: Greater polymorphism was observed in several genes in families with familial MS compared to the general population; this may reflect greater susceptibility to autoimmune diseases. Pedigree analysis also revealed that LT‐α variants rs1041981 and rs2229094 and LT‐β variant rs4647197 were associated with MS and that LT‐β variant rs4647183 was associated with other autoimmune diseases. The association between autoimmune disease and TNFAIP2 variant rs1132339 is particularly noteworthy, as is the fact that TNFAIP6 variant rs1046668 appears to follow a recessive inheritance pattern.Conclusions: Our findings support the idea that the risk of familial MS is associated with variants of signaling pathways, including those involving TNF‐α.
- Open Access
- 9 July 2020
- Published by Wiley in Journal of Medical Virology
- Vol. 93 (1) , 546-549
Clinical exacerbation of SARS‐CoV2 infection after fingolimod withdrawal
The role of disease‐modifying therapies in patients with autoimmune disorders during severe acute respiratory syndrome coronavirus 2 (SARS‐CoV2) infection is controversial. Immunocompromised patients could have a more severe coronavirus disease‐2019 (COVID‐19) due to the absence of an adequate immune response against the SARS‐CoV‐2. However, therapies that act on immune response could play a protective role by dampening the cytokine‐release syndrome. Fingolimod is a drug used for immune therapy in patients with multiple sclerosis (MS) through the sequestration of activated lymphocytes in the lymph nodes. We report the case of a 57‐year‐old man with relapsing‐remitting MS treated with fingolimod that showed a reactivation of COVID‐19 with signs of hyperinflammation syndrome after fingolimod withdrawal. Our case suggests that discontinuation of fingolimod during COVID‐19 could imply a worsening of SARS‐CoV2 infection.
- 9 July 2020
- Published by Wiley in Journal of Medical Virology
- Vol. 93 (1) , 546-549
Open AccessClinical exacerbation of SARS‐CoV2 infection after fingolimod withdrawal
The role of disease‐modifying therapies in patients with autoimmune disorders during severe acute respiratory syndrome coronavirus 2 (SARS‐CoV2) infection is controversial. Immunocompromised patients could have a more severe coronavirus disease‐2019 (COVID‐19) due to the absence of an adequate immune response against the SARS‐CoV‐2. However, therapies that act on immune response could play a protective role by dampening the cytokine‐release syndrome. Fingolimod is a drug used for immune therapy in patients with multiple sclerosis (MS) through the sequestration of activated lymphocytes in the lymph nodes. We report the case of a 57‐year‐old man with relapsing‐remitting MS treated with fingolimod that showed a reactivation of COVID‐19 with signs of hyperinflammation syndrome after fingolimod withdrawal. Our case suggests that discontinuation of fingolimod during COVID‐19 could imply a worsening of SARS‐CoV2 infection.
- Open Access
- 5 June 2020
- Published by Wiley in Movement Disorders
- Vol. 35 (7) , 1104-1105
SARS‐CoV‐2 as a Potential Trigger of Neurodegenerative Diseases
- 5 June 2020
- Published by Wiley in Movement Disorders
- Vol. 35 (7) , 1104-1105
Open AccessSARS‐CoV‐2 as a Potential Trigger of Neurodegenerative Diseases
- 21 May 2020
- Published by Wiley in Journal of Medical Virology
- Vol. 92 (11) , 2354-2355
Is the brain a reservoir organ for SARS‐CoV2?
- 21 May 2020
- Published by Wiley in Journal of Medical Virology
- Vol. 92 (11) , 2354-2355
Is the brain a reservoir organ for SARS‐CoV2?
- Open Access
- 26 March 2018
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 20 (3) , e89
Detecting Motor Impairment in Early Parkinson’s Disease via Natural Typing Interaction With Keyboards: Validation of the neuroQWERTY Approach in an Uncontrolled At-Home Setting
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet
- 26 March 2018
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 20 (3) , e89
Open AccessDetecting Motor Impairment in Early Parkinson’s Disease via Natural Typing Interaction With Keyboards: Validation of the neuroQWERTY Approach in an Uncontrolled At-Home Setting
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet
- Open Access
- 20 November 2017
- Published by JMIR Publications Inc. in JMIR Preprints
Detecting Motor Impairment in Early Parkinson s Disease via Natural Typing Interaction With Keyboards: Validation of the neuroQWERTY Approach in an Uncontrolled At-Home Setting (Preprint)
BACKGROUND Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease and one of the most common forms of movement disorder. Although there is no known cure for PD, existing therapies can provide effective symptomatic relief. However, optimal titration is crucial to avoid adverse effects. Today, decision making for PD management is challenging because it relies on subjective clinical evaluations that require a visit to the clinic. This challenge has motivated recent research initiatives to develop tools that can be used by nonspecialists to assess psychomotor impairment. Among these emerging solutions, we recently reported the neuroQWERTY index, a new digital marker able to detect motor impairment in an early PD cohort through the analysis of the key press and release timing data collected during a controlled in-clinic typing task. OBJECTIVE The aim of this study was to extend the in-clinic implementation to an at-home implementation by validating the applicability of the neuroQWERTY approach in an uncontrolled at-home setting, using the typing data from subjects’ natural interaction with their laptop to enable remote and unobtrusive assessment of PD signs. METHODS We implemented the data-collection platform and software to enable access and storage of the typing data generated by users while using their computer at home. We recruited a total of 60 participants; of these participants 52 (25 people with Parkinson’s and 27 healthy controls) provided enough data to complete the analysis. Finally, to evaluate whether our in-clinic-built algorithm could be used in an uncontrolled at-home setting, we compared its performance on the data collected during the controlled typing task in the clinic and the results of our method using the data passively collected at home. RESULTS Despite the randomness and sparsity introduced by the uncontrolled setting, our algorithm performed nearly as well in the at-home data (area under the receiver operating characteristic curve [AUC] of 0.76 and sensitivity/specificity of 0.73/0.69) as it did when used to evaluate the in-clinic data (AUC 0.83 and sensitivity/specificity of 0.77/0.72). Moreover, the keystroke metrics presented a strong correlation between the 2 typing settings, which suggests a minimal influence of the in-clinic typing task in users’ normal typing. CONCLUSIONS The finding that an algorithm trained on data from an in-clinic setting has comparable performance with that tested on data collected through naturalistic at-home computer use reinforces the hypothesis that subtle differences in motor function can be detected from typing behavior. This work represents another step toward an objective, user-convenient, and quasi-continuous monitoring tool for PD.
- 20 November 2017
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessDetecting Motor Impairment in Early Parkinson s Disease via Natural Typing Interaction With Keyboards: Validation of the neuroQWERTY Approach in an Uncontrolled At-Home Setting (Preprint)
BACKGROUND Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease and one of the most common forms of movement disorder. Although there is no known cure for PD, existing therapies can provide effective symptomatic relief. However, optimal titration is crucial to avoid adverse effects. Today, decision making for PD management is challenging because it relies on subjective clinical evaluations that require a visit to the clinic. This challenge has motivated recent research initiatives to develop tools that can be used by nonspecialists to assess psychomotor impairment. Among these emerging solutions, we recently reported the neuroQWERTY index, a new digital marker able to detect motor impairment in an early PD cohort through the analysis of the key press and release timing data collected during a controlled in-clinic typing task. OBJECTIVE The aim of this study was to extend the in-clinic implementation to an at-home implementation by validating the applicability of the neuroQWERTY approach in an uncontrolled at-home setting, using the typing data from subjects’ natural interaction with their laptop to enable remote and unobtrusive assessment of PD signs. METHODS We implemented the data-collection platform and software to enable access and storage of the typing data generated by users while using their computer at home. We recruited a total of 60 participants; of these participants 52 (25 people with Parkinson’s and 27 healthy controls) provided enough data to complete the analysis. Finally, to evaluate whether our in-clinic-built algorithm could be used in an uncontrolled at-home setting, we compared its performance on the data collected during the controlled typing task in the clinic and the results of our method using the data passively collected at home. RESULTS Despite the randomness and sparsity introduced by the uncontrolled setting, our algorithm performed nearly as well in the at-home data (area under the receiver operating characteristic curve [AUC] of 0.76 and sensitivity/specificity of 0.73/0.69) as it did when used to evaluate the in-clinic data (AUC 0.83 and sensitivity/specificity of 0.77/0.72). Moreover, the keystroke metrics presented a strong correlation between the 2 typing settings, which suggests a minimal influence of the in-clinic typing task in users’ normal typing. CONCLUSIONS The finding that an algorithm trained on data from an in-clinic setting has comparable performance with that tested on data collected through naturalistic at-home computer use reinforces the hypothesis that subtle differences in motor function can be detected from typing behavior. This work represents another step toward an objective, user-convenient, and quasi-continuous monitoring tool for PD.